Autologous chimeric antigen receptor T cell therapy is one of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients’ T cells, which fight hostile cells within the body. This revolutionary technology has brought up some of the best cancer drug stocks we have ever seen.
Moreover, unlike other cancer treatments, CAR T drugs enlist cells that come from the patients themselves in the cancer-fighting effort. Here are three of the best cancer drug stocks that can advance tremendously, thanks in large part to the CAR T drugs that they’re developing.
This post appeared first on InvestorPlace.